hotspot -WSS

hotspot

author：knowledge 2025-09-30 18:43:24 - browse：21193

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： How generative AI is inspiring dreams of a health data revolution

focus

WSS

House transparency, PBM reform bill gains bipartisan support

NIH nominee Bertagnolli will get October confirmation hearing

'Make People Better': The CRISPR babies story you probably don't know

Amazon on where the company's health care bets are headed next

The (many) problems with a new study criticizing cancer screening

The 10 drugs up first for Medicare price negotiation

knowledge

hotspot

focus

23andMe had bad news about my health. I wish a person had delivered it

Why Novartis is changing the name of its research labs

Affirmative action in medical school literally saved lives

AstraZeneca chief proposes a novel edit to the drug pricing bill

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicaid rebukes states for mistakenly disenrolling children

Medical leaders decry Supreme Court decision on affirmative action

The (many) problems with a new study criticizing cancer screening

ChatGPT in medicine: STAT answers readers' burning questions

Humana sues Biden admin over Medicare Advantage audit rule

hotspot

What American doctors can learn from their Israeli counterparts

Weighted lottery helped low

Advances in CAR

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

House transparency, PBM reform bill gains bipartisan support

hotspot

Wikipedia

focus

Wikipedia